Evidence map›Paper›PMID 39049770›Full record

ReviewFuture cardiology2024

Clinical trial evaluation: the EDOSURE clinical trial program.

Michael Griffin, Gregory Yh Lip

Abstract readReview
In one paragraph

Review in Future cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael GriffinLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University & Liverpool Heart & Chest Hospital, L14 3PE, Liverpool, UK.ORCID 0009-0007-8510-2944
Gregory Yh LipLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University & Liverpool Heart & Chest Hospital, L14 3PE, Liverpool, UK.ORCID 0000-0002-7566-1626

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EDOSURE is a trial program of the direct oral anticoagulant drug edoxaban, comprising ten randomized clinical trials of which eight are currently published. They evaluate the use of edoxaban in the treatment of nonvalvular atrial fibrillation and acute venous thromboembolism, including in special circumstances such as patients undergoing cardiac procedures, cancer-associated venous thromboembolism, and elderly patients whose bleeding risk precludes conventional anticoagulation strategies. As a result of the collective evidence generated by EDOSURE, edoxaban is now recommended as a treatment option by numerous international guidelines. This review summarizes the context, rationale, and key findings of the studies.

Indexed as

Atrial FibrillationPyridinesThiazolesVenous ThromboembolismAnticoagulantsFactor Xa InhibitorsHumansRandomized Controlled Trials as TopicAnticoagulantsedoxabanFactor Xa InhibitorsPyridinesThiazolesatrial fibrillationedoxabanstrokevenous thromboembolism

Identifiers

PMID39049770
PMCPMC11285212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.